Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02038829
Recruitment Status : Completed
First Posted : January 17, 2014
Results First Posted : January 25, 2018
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Sunovion Respiratory Development Inc.

Brief Summary:
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.

Condition or disease Intervention/treatment Phase
COPD Drug: Placebo Drug: SUN101 3 mcg Drug: SUN-101 6.25 mcg Drug: SUN-101 12.5 mcg Drug: SUN-101 50 mcg Drug: Aclidinium Phase 2

Detailed Description:
This is a randomized, six-way crossover study to determine the efficacy and dose-response profile of SUN101. The study population will consist of subjects 40 to 65 years-old (inclusive), with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg bid will be given as an active comparator. The study will be double-blind for SUN-101 and placebo and will be open-label for aclidinium.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Study Start Date : January 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo bid
Drug: Placebo
Placebo

Experimental: SUN-101 3 mcg
SUN-101 3 mcg bid
Drug: SUN101 3 mcg
SUN-101 3 mcg bid

Experimental: SUN-101 6.25 mcg
SUN-101 6.25 mcg bid
Drug: SUN-101 6.25 mcg
SUN-101 6.25 mcg bid

Experimental: SUN-101 12.5 mcg
SUN-101 12.5 mcg bid
Drug: SUN-101 12.5 mcg
SUN-101 12.5 mcg bid

Experimental: SUN-101 50 mcg
SUN-101 50 mcg bid
Drug: SUN-101 50 mcg
SUN-101 50 mcg bid

Active Comparator: Aclidinium 400 mcg
Aclidinium 400 mcg bid
Drug: Aclidinium
Aclidinium 400 mcg bid




Primary Outcome Measures :
  1. Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo. [ Time Frame: Baseline and Day 7 ]
    Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the 2 spirometry values collected at 23 hours 15 minutes, and 23 hours 45 minutes post-morning dose on Day 7 of each Treatment Period. The FEV1 values within 6 hours after the use of rescue medication were considered as missing. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period


Secondary Outcome Measures :
  1. Standardized Change From Baseline in FEV1 AUC(0-12hours) [ Time Frame: Day 7 ]
    The standardized FEV1 AUC(0-12) on Day 7 was calculated using the trapezoidal rule from the changes in FEV1 from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval).

  2. Number of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment) [ Time Frame: Over 7 days ]
    A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.

  3. Percentage of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment) [ Time Frame: Over 7 days ]
    A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients 40 to 65 years-old, inclusive.
  2. A clinical diagnosis of moderate to severe COPD according to the GOLD 2011 guidelines.
  3. Current smokers or ex-smokers with at least 10 pack year smoking history (eg, at least 1 pack/day for 10 years, or equivalent).
  4. Post bronchodilator (following inhalation of ipratropium bromide) FEV1 ≥ 40% and ≤ 70% of predicted normal during Screening.
  5. Post bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio ≤ 0.70 during Screening.
  6. Post bronchodilator (following inhalation of ipratropium bromide) improvement in FEV1 ≥ 12% and ≥ 100 mL during Screening.
  7. Ability to perform reproducible spirometry according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines (2005).
  8. Female of child bearing potential (only) must have a negative serum pregnancy test at Screening and be neither breastfeeding nor intending to become pregnant during study participation. Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study. Female subjects of child bearing potential must use an adequate method of birth control from Screening until 30 days after receiving study drug and use contraception in addition to their partners using a barrier method. Acceptable forms of contraception are as follows:

    • Abstinence
    • Barrier methods: condoms, diaphragms, cervical caps; with a spermicide foam, gel, film, cream or suppository;
    • Oral contraceptives
    • Non hormone containing intrauterine methods: intrauterine devices or systems.
  9. Willing and able to remain at the study site for at least 24 hours at Day 7 of each Treatment Period.
  10. Willing and able to attend all study visits and adhere to all study assessments/procedures.
  11. Willing and able to provide written informed consent

Exclusion Criteria:

  1. Current evidence or recent history of any clinically significant and unstable disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data; including but not limited to cardiovascular disease, myocardial infarction, cardiac failure, uncontrolled hypertension, life threatening arrhythmias, uncontrolled diabetes, neurologic or neuromuscular disease, liver disease, gastrointestinal disease or electrolyte abnormalities.
  2. Current evidence or history of a clinically significant abnormality of cardiac rhythm and/or conduction including Holter monitoring prior to randomization.
  3. Primary diagnosis of asthma.
  4. History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin.
  5. Recent history of COPD exacerbation requiring hospitalization or need for increased treatments for COPD within 6 weeks prior to Screening.
  6. Use of daily oxygen therapy > 10 hours per day.
  7. Use of systemic steroids within 3 months prior to Screening.
  8. Respiratory tract infection within 6 weeks prior to or during Screening.
  9. History of tuberculosis, bronchiectasis or other non-specific pulmonary disease.
  10. History of urinary retention or bladder neck obstruction type symptoms.
  11. History of narrow angle glaucoma.
  12. Prolonged QTcF interval (males > 450 msec and females >470 msec) during Screening, or history of long QT syndrome.
  13. Recent history (previous 12 months) of excessive use or abuse of alcohol or narcotic/illegal drugs.
  14. History of hypersensitivity or intolerance to aerosol medications, beta-2 agonists, or anticholinergics.
  15. Participation in another investigational drug study where drug was received within 30 days prior to Screening, or current participation in another investigational drug trial.
  16. Subject is a staff member of the clinical site or a relative of a clinical site staff member.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02038829


Locations
Layout table for location information
United States, Florida
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States, 33765
United States, North Carolina
American Health Research, Inc.
Charlotte, North Carolina, United States, 28207
North Carolina Clinical Research
Raleigh, North Carolina, United States, 27607
United States, Oregon
Clinical Research Institute of Southern Oregon, PC
Medford, Oregon, United States, 97504
United States, South Carolina
Palmetto Medical Research Associates, LLC
Easley, South Carolina, United States, 29640
Greenville Pharmaceutical Research, Inc.
Greenville, South Carolina, United States, 29615
Upstate Pharmaceutical Research
Greenville, South Carolina, United States, 29615
S. Carolina
Spartanburg, South Carolina, United States, 29303
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303
CU Pharmaceutical Research
Union, South Carolina, United States, 29379
Sponsors and Collaborators
Sunovion Respiratory Development Inc.
Investigators
Layout table for investigator information
Study Director: SUN101 Medical Director, MD Sunovion

Publications of Results:
Layout table for additonal information
Responsible Party: Sunovion Respiratory Development Inc.
ClinicalTrials.gov Identifier: NCT02038829     History of Changes
Other Study ID Numbers: SUN101-201
First Posted: January 17, 2014    Key Record Dates
Results First Posted: January 25, 2018
Last Update Posted: April 10, 2018
Last Verified: March 2018

Keywords provided by Sunovion Respiratory Development Inc.:
COPD